Crossover RCT | Efficacy of low-dose Empagliflozin as an adjunct to hybrid closed-loop insulin therapy in adults with Type 1 DM.
7 Nov, 2022 | 12:24h | UTCLow-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial – Diabetes Care (link to abstract – $ for full-text)